Research Funding

Grant Title Grantor Amount Award Date
Nicole Hamblett, PhD
Rates of Hemoptysis Among Individuals with Cystic Fibrosis Enrolled in Clinical Trials Pharmaxis Ltd. Feb. 1, 2014
Nicole Hamblett, PhD
Long Term Outcomes After Eradication of Pseudomonas Aeruginosa Among Children Enrolled in EPIC Clinical Novartis Pharmaceuticals Corp. Dec. 15, 2013
Nicole Hamblett, PhD
Optimizing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE NIH/NHLBI Sept. 15, 2013
Bonnie W. Ramsey, MD
Optimizing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter Randomized Trial Clinical Coordinating Center NIH/NHLBI Sept. 15, 2013
Benjamin S. Wilfond, MD
ITHS Supplement - Attitudes about the Ethics of Standard of Care Research NIH/NCATS Sept. 13, 2013
Nicole Hamblett, PhD
G551D Observational Study Expanded to Include Additional Genotypes and Extended for Long Term Followup Cystic Fibrosis Foundation Therapeutics Sept. 1, 2013
Benjamin S. Wilfond, MD
Clinical Implementation of Carrier Testing Using NGS NIH/NHGRI June 15, 2013
Bonnie W. Ramsey, MD
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS) Cystic Fibrosis Foundation Therapeutics Oct. 1, 2012
Bonnie W. Ramsey, MD
Baby Observational and Nutritional Study of Cystic Fibrosis (BONUS) NIH/NIDDK Aug. 3, 2012
Nicole Hamblett, PhD
A Multicenter Study of the Effects of AquADEKs-2 on Markers of Inflammation and Oxidative Stress in CF Cystic Fibrosis Foundation Therapeutics Aug. 1, 2012
Sonya Heltshe, PhD
Cell Phone Spirometry Pilot in CF Patients Coulter Foundation July 1, 2012
Bonnie W. Ramsey, MD
Institute for Translational Health Sciences NIH June 1, 2012
Benjamin S. Wilfond, MD
Institute of Translational Health Sciences NIH/NCATS June 1, 2012
Bonnie W. Ramsey, MD
Molecular Biology of Cystic Fibrosis Cystic Fibrosis Foundation Oct. 1, 2011
Bonnie W. Ramsey, MD
Early Intervention in CF Exacerbation (eICE Study) Cystic Fibrosis Foundation Therapeutics Aug. 1, 2011
Bonnie W. Ramsey, MD
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS) NIH/NHLBI Aug. 1, 2011
Bonnie W. Ramsey, MD
Infant Nutrition Study of Newborns with Cystic Fibrosis Cystic Fibrosis Foundation Therapeutics Feb. 1, 2011
Bonnie W. Ramsey, MD
Newly Acquired MRSA Eradication Protocol Cystic Fibrosis Foundation Therapeutics Sept. 1, 2010
Bonnie W. Ramsey, MD
Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis NIH/NIDDK July 6, 2010
Sonya Heltshe, PhD
Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis (P30) NIH/NIDDK July 6, 2010
Bonnie W. Ramsey, MD
Early Intervention in Pulmonary Exacerbation in CF NIH/NHLBI July 1, 2010
Benjamin S. Wilfond, MD
Center for Genomics and Healthcare Equity NIH/NHGRI May 14, 2010
Nicole Hamblett, PhD
Pseudomonas Aeruginosa Adaptation During Early CF Airway Infection and Treatment NIH Sept. 11, 2009
Bonnie W. Ramsey, MD
EPIC Observational Study Cystic Fibrosis Foundation Therapeutics April 1, 2009
Nicole Hamblett, PhD
Institute of Translational Health Sciences NIH/NCATS Sept. 17, 2007
Gregory J. Redding, MD
PEDIATRIC PULMONARY TRAINING GRANT, SEATTLE, WASHINGTON U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, MATERNAL AND CHILD HEALTH BUREAU, HRSA July 1, 2005
Bonnie W. Ramsey, MD
Therapeutics Development Network Coordinating Center Cystic Fibrosis Foundation Therapeutics April 1, 2003
Sonya Heltshe, PhD
Therapeutics Development Network Coordinating Center Cystic Fibrosis Foundation Therapeutics April 1, 2003
Maida Lynn Chen, MD
CPAP Adherence Factors
Maida Lynn Chen, MD
Sleep, Temperament, and Arousal Regulation in Infants with Prenatal Exposure CCTR
Maida Lynn Chen, MD
Midface and Positive Airway Pressure (MAP)
Maida Lynn Chen, MD
A Multicenter Retrospective with Prospective follow-Up Study of Early Onset Childhood Narcolepsy: Recent cases and Post infection (EON) Jazz
Jason Scott Debley, MD, MPH
Noninvasive Measures of Airway Inflammation and Airflow Obstruction in Wheezy Infants and Toddlers
Jason Scott Debley, MD, MPH
Airway Epithelial Cell Cytokine Profiles of Children with and without Asthma NIH/NIAID, NIH/NHLBI, Benaroya Research Institute, Amgen, Firlands Foundation
Ron Gibson, MD, PhD
Early MRSA Therapy in CF- culture based vs observant therapy (treat or observe) (STAR-too) Cystic Fibrosis Foundation
Ron Gibson, MD, PhD
A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) Versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis Patients MPex
Ron Gibson, MD, PhD
I Change Adherence and Raise Expectations Novartis
Ron Gibson, MD, PhD
Early Intervention in CF Exacerbation NIH
Ron Gibson, MD, PhD
Cystic Fibrosis Foundation National Patient Registry Cystic Fibrosis Foundation
Ron Gibson, MD, PhD
Co-director, Clinical Core, P30 Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis NIH
Ron Gibson, MD, PhD
Director, Clinical Core, Cystic Fibrosis Research Development Program Cystic Fibrosis Foundation
Ron Gibson, MD, PhD
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH) NIH
Ron Gibson, MD, PhD
CF EPIC Participation in the NHLBI Lung Cohorts Sequencing Project NIH
Ron Gibson, MD, PhD
The EPIC Observational Study: Longitudinal Assessment of Risk Factors and Impact of Pseudomonas aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF (Protocol # EPIC-002) Cystic Fibrosis Foundation $
Ron Gibson, MD, PhD
Comparison study of regulatory T cell phenotypes and function in blood samples from individuals with CF and healthy non-CF controls Cystic Fibrosis Foundation
Ron Gibson, MD, PhD
A Phase 3, Blinded, Rollover Study to Evaluate the Safety and Efficacy of Long-Term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (VX12-809-105) Vertex
Ron Gibson, MD, PhD
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (VX12-809-103 Vertex
Ron Gibson, MD, PhD
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects with Cystic Fibrosis Who Have the R117H-CFTR Mutation (VX11-770-110) Vertex
Ron Gibson, MD, PhD
An Open-Label, Rollover Study to Evaluate the Long-Term Safety and Efficacy of VX-770 in Subjects with Cystic Fibrosis (VX08-770-105) Vertex
Ron Gibson, MD, PhD
Role of Islet Amyloid and IL-1 Signaling in -cell Loss in Cystic Fibrosis Related Diabetes NIH
Ron Gibson, MD, PhD
Cystic Fibrosis Bronchoalveolar Lavage Fluid Specimen Bank Cystic Fibrosis Foundation
Luke Hoffman, MD, PhD
Pseudomonas aeruginosa adaptation During Early Cystic Fibrosis Airway Infection and Treatment Cystic Fibrosis Foundation
Luke Hoffman, MD, PhD
Changes in CF Respiratory Microbiota During Treatment With Kalydeco in People with the G551D Mutation NIH
Luke Hoffman, MD, PhD
The roles of Staphylococcus aureus and Pseudomonas aeruginosa adapted forms in cystic fibrosis (CF) lung disease Cystic Fibrosis Foundation
Luke Hoffman, MD, PhD
Community-level Physiologic Profiling of Whole Cystic Fibrosis Sputum Cystic Fibrosis Foundation
Luke Hoffman, MD, PhD
Describing the CF Gut Microbiome in Infancy and Early Childhood NIH
Luke Hoffman, MD, PhD
The relationship of fecal microbiomes and nutritional status in CF Cystic Fibrosis Foundation
Luke Hoffman, MD, PhD
High-resolution fluorescent microscopic characterization of CF polymicrobial lung infections Cystic Fibrosis Foundation
Luke Hoffman, MD, PhD
Staphylococcus aureus small-colony variants: Optimal testing and treatment CCTR
Luke Hoffman, MD, PhD
Baby Observational and Nutrition Study Cystic Fibrosis Foundation
Thida Ong, MD
Prospective Cohort Study of Severe Bronchiolitis and Risk of Recurrent Wheezing NIH
Margaret Rosenfeld, MD, MPH
Testing a Multifactorial Caries Model for Pediatric Patients with Cystic Fibrosis Sunstar and Cystic Fibrosis Foundation
Margaret Rosenfeld, MD, MPH
Early Onset and Progression of Primary Ciliary Dyskinesia Lung Disease Prior to 10 Years of Age (RDN #5903) NIH
Margaret Rosenfeld, MD, MPH
Longitudinal Study of Primary Ciliary Dyskinesia: Participants 5 -18 Years of Age (Protocol 5901) NIH
Margaret Rosenfeld, MD, MPH
Study of Inhaled Saline in Preschool Children with CF (SHIP): Planning Grant Cystic Fibrosis Foundation
Margaret Rosenfeld, MD, MPH
Development of an Observer Reported Outcome of Respiratory Signs for Young Children with Cystic Fibrosis CCTR
Margaret Rosenfeld, MD, MPH
A Phase 1, Open-Label Study to evaluate the Pharmacokinetics and Safety of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (VX12-809-011) Vertex
Margaret Rosenfeld, MD, MPH
A Phase 3, 2 Arm, Roll-Over Study to Evaluate the Long Term Safety and Pharmacodynamics of Ivacaftor Treatment in Pediatric Subjects With Cystic Fibrosis and a CFTR Gating Mutation (VX11-770-109) Vertex
Margaret Rosenfeld, MD, MPH
A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis and a CFTR Gating Mutation, Age 2to 5Years (VX11-770-108) Vertex
Margaret Rosenfeld, MD, MPH
Infant Study of Inhaled Saline NIH and Cystic Fibrosis Foundation
Margaret Rosenfeld, MD, MPH
Parent Report of Respiratory and Gastrointestinal Signs in Infants and Young Children with Cystic Fibrosis: A Feasibility study CCTR
Margaret Rosenfeld, MD, MPH
The EPIC Observational Study: Longitudinal Assessment of Risk Factors and Impact of Pseudomonas aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF (Protocol # EPIC-002) Cystic Fibrosis Foundation
Margaret Rosenfeld, MD, MPH
Novel Home Cough Monitor in Young Children with Cystic Fibrosis: A Pilot and Feasibility Study CCTR
Margaret Rosenfeld, MD, MPH
Validation of a novel cell-phone spirometer in pediatric patients with respiratory diseases ITHS and Coulter Foundation
Yemiserach Kifle, MD
Foramen Magnum Stenosis in Achondroplasia: The Value of Screening by Polysomnography
Amanda Striegl, MD, MS
Spinal Muscular Atrophy Research Database: A Multicenter Multidisciplinary Assessment Families of Spinal Muscular Atrophy